| Revenue Growth | US 6.7M euros (29% sequential); International 2.5M euros (42% YoY). |
|---|---|
| Mgmt Confidence | Confident in US launch; disappointed by guidance adjustment but proud of momentum. |
| Demand Visibility | 447 patients in prior authorization; 233 active accounts; 342 surgeons trained. |
| Margin Trends | Gross margin 63.1%, up 260bps YoY; FY26 target 60-62%. |
| Op. Leverage | Shifting spend from R&D to commercial; cash burn reduced by 2.5M euros. |
| Pricing Power | CMS 2027 outpatient reimbursement increasing 11% to $35,072; ASC up 13%. |
| Vol vs Price | Growth driven by US commercial launch volume and account activation. |
| Segment Growth | US revenue is primary driver; international performing in line with expectations. |
| New Clients | Activated 53 new accounts and trained 18 new surgeons in Q3. |
| Capex & Debt | Cash and financial assets at 77.1M euros as of September 30. |
| Regulatory | PMA supplement submitted for CCC indication; Access study met co-primary endpoints. |
| Commentary | Refocusing from R&D-centric to a commercially-centric organization under new CEO leadership. |
| New Launches | US commercial launch of Genio; pending FDA approval for CCC indication expansion. |
Growth
US revenue grew 29% sequentially to 6.7M euros; international grew 42% YoY to 2.5M euros.
Outlook
FY2026 revenue guided to 33M-35M euros; gross margins expected between 60% and 62%.
Risks
Management cut FY26 guidance and pivoted away from providing specific 2027 sequential growth targets during Q&A.
Source
Read the 8-K ↗
The company's earnings call, and its 8-K filed with the SEC. Summary written with AI assistance from the call.